Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2010 October;58(5) > Minerva Cardioangiologica 2010 October;58(5):589-98

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  INTENSIVE CARDIAC CARE - PART II


Minerva Cardioangiologica 2010 October;58(5):589-98

language: English

Reduction of mitral valve regurgitation with Mitraclip® percutaneous system

Tamburino C., Immè S., Barbanti M., Mulè M., Pistritto A. M., Aruta P., Cammalleri V., Scarabelli M., Mangiafico S., Scandura S., Ussia G. P.

1 Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;
2 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy


PDF  


Mitral regurgitation (MR) is the second most common heart valve disease worldwide and the current gold-standard treatment is surgical repair or replacement. Nevertheless, many patients do not undergo surgical intervention due to several comorbidities. Percutaneous “edge-to-edge” mitral valve repair using the MitraClip System is an emerging and effective option to this subset of patients. This device has been used to treat both functional and degenerative mitral valve regurgitation and has been compared to surgery in the Endovascular Valve Edge-to-Edge Repair Study II (EVEREST II) randomized trial. Although the field of percutaneous management of MR is at an early stage, it has been demonstrated that percutaneous approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.

top of page

Publication History

Cite this article as

Corresponding author e-mail

gpussia@hotmail.com